{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:25"], "contactPoint": {"@type": "vcard:Contact", "fn": "NIH", "hasEmail": "mailto:info@nih.gov"}, "description": "In recent years, the effectiveness of anti-TNF therapy in treating rheumatoid arthritis (RA) has become apparent. While trials of IL-1 receptor antagonist in RA have been encouraging, it clearly is more difficult to target two molecules (IL-1 \u03b1 and \u03b2) than one (TNF-\u03b1). In his review article, Professor Wim van den Berg argues that both TNF-\u03b1 and IL-1 must be blocked in RA and that although TNF is clearly a potent inflammatory molecule, the dominant cytokine in the subsequent degradation of the joint tissue is IL-1. This commentary discusses his hypothesis in light of animal studies and the limitations of the conclusions that can be drawn from them. More broadly, it discusses the biology of TNF-\u03b1 and IL-1 and suggests explanations of why TNF-\u03b1 is a pivotal cytokine in this disease.", "distribution": [{"@type": "dcat:Distribution", "description": "Visit the original government dataset for complete information, documentation, and data access.", "downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128897/", "mediaType": "text/html", "title": "Official Government Data Source"}], "identifier": "https://healthdata.gov/api/views/a6er-36e2", "issued": "2025-07-14", "keyword": ["anti-tnf-therapy", "cytokine-therapy", "il-1-antagonist", "nih", "rheumatoid-arthritis"], "landingPage": "https://healthdata.gov/d/a6er-36e2", "modified": "2025-09-06", "programCode": ["009:048"], "publisher": {"@type": "org:Organization", "name": "National Institutes of Health"}, "theme": ["NIH"], "title": "A follow-up to \"Anti-cytokine therapy in chronic destructive arthritis\" by Wim B van den Berg"}